Diamonds in the Rough
Cross-referencing fundamental value against technical exhaustion to isolate beaten-down ARKG constituents that screen cheap and oversold. The bottom-right quadrant — high earnings yield, low RSI — is the prime hunting ground, especially where money flow (MFI) shows quiet accumulation despite the falling price.
Educational screen, not investment advice. “Diamond” classification is a mechanical valuation-vs-RSI split around the cohort median earnings yield and an RSI of 50.
Alpha Quadrant — Valuation × Technical Exhaustion
X = earnings yield (cheaper right) · Y = RSI 14 (more oversold lower) · bubble = market cap · color = money flow.
Diamond Candidates
Ranked by a composite of earnings yield, ROIC, oversold RSI, recent weakness, and improving money flow.
| # | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | LLY | Eli Lilly & Co. | 44.5 | 3.16% | 0.73 | 43 | -1.83% | 60 | safe |
| 2 | CERS | Cerus Corp | 32.2 | -0.32% | -0.02 | 33 | -13.31% | 49 | distress |
| 3 | CMPS | COMPASS Pathways Plc American Depository Shares | 30.0 | -14.37% | -1.68 | 35 | -10.59% | 32 | distress |
| 4 | NRIX | Nurix Therapeutics, Inc. Common stock | 30.0 | -15.58% | -0.89 | 34 | -12.75% | 44 | safe |
| 5 | IONS | Ionis Pharmaceuticals, Inc. Common Stock | 30.0 | -7.24% | -0.26 | 30 | -27.73% | 34 | safe |
| 6 | SCTX | Scribe Therapeutics Inc. Common Stock | 30.0 | -- | -- | 32 | -43.56% | 45 | -- |
| 7 | GENB | Generate Biomedicines, Inc. Common Stock | 28.7 | -- | -- | 36 | -13.08% | 42 | -- |
| 8 | BEAM | Beam Therapeutics Inc. Common Stock | 28.2 | -15.69% | -0.32 | 42 | -16.30% | 56 | safe |
| 9 | WGS | GeneDx Holdings Corp. Class A Common Stock | 27.7 | -4.17% | -0.41 | 37 | -12.93% | 41 | distress |
| 10 | VCYT | Veracyte, Inc. | 25.7 | 3.13% | 0.20 | 54 | +5.29% | 60 | safe |
| 11 | ILMN | Illumina Inc | 24.9 | 2.09% | 0.44 | 70 | +30.88% | 88 | safe |
| 12 | PRME | Prime Medicine, Inc. Common Stock | 22.4 | -39.86% | -3.06 | 43 | -14.86% | 46 | distress |
| 13 | ARCT | Arcturus Therapeutics Holdings Inc. Common Stock | 19.5 | -57.19% | -0.61 | 46 | -20.84% | 44 | distress |
| 14 | PSNL | Personalis, Inc. Common Stock | 17.5 | -6.95% | -0.46 | 53 | -5.02% | 68 | safe |
| 15 | CRSP | CRISPR Therapeutics AG | 17.4 | -9.45% | -0.23 | 51 | -2.98% | 67 | safe |
Short-Squeeze Watch
Constituents with the highest composite squeeze score — heavy short interest meeting price support.
| # | |||||||
|---|---|---|---|---|---|---|---|
| 1 | ABSI | Absci Corporation Common Stock | 90.2 | 31.21% | 14.44 | +24.38% | critical |
| 2 | PRME | Prime Medicine, Inc. Common Stock | 84.7 | 33.59% | 12.31 | -14.86% | critical |
| 3 | WGS | GeneDx Holdings Corp. Class A Common Stock | 82.9 | 31.33% | 12.09 | -12.93% | critical |
| 4 | RXRX | Recursion Pharmaceuticals, Inc. Class A Common Stock | 81.4 | 41.37% | 12.56 | +23.35% | critical |
| 5 | NTLA | Intellia Therapeutics, Inc | 80.8 | 40.57% | 14.10 | -3.24% | critical |
| 6 | BEAM | Beam Therapeutics Inc. Common Stock | 79.4 | 31.57% | 12.59 | -16.30% | critical |
| 7 | PACB | Pacific Biosciences of California, Inc. | 78.2 | 19.58% | 10.49 | +96.90% | critical |
| 8 | CRSP | CRISPR Therapeutics AG | 75.6 | 23.06% | 16.54 | -2.98% | critical |
| 9 | TWST | Twist Bioscience Corporation Common Stock | 71.1 | 23.33% | 8.92 | +43.55% | high |
| 10 | SDGR | Schrodinger, Inc. Common Stock | 68.8 | 21.31% | 8.74 | +46.64% | high |
| 11 | ARCT | Arcturus Therapeutics Holdings Inc. Common Stock | 68.2 | 24.01% | 6.37 | -20.84% | high |
| 12 | MASS | 908 Devices Inc. Common Stock | 67.7 | 9.84% | 9.29 | +18.60% | high |
Market cap, valuation, and short-interest metrics are joined to the latest ARKG holdings snapshot; each ticker links to its full quote and analysis page.